Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: F18 Fluciclovine Clear all
Completed Phase 2 Interventional Results available

Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone

NCT03707184
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
Interventions
Computed Tomography, Fluciclovine F18, Positron Emission Tomography
Procedure · Drug
Lead sponsor
University of Utah
Other
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 29, 2026, 11:28 AM EDT
Completed Phase 2 Interventional

Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery

NCT03515577
View directory record Official record
Conditions
Recurrent Prostate Carcinoma
Interventions
Computed Tomography, Fluciclovine F18, Gallium Ga 68-labeled PSMA-11, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 29, 2026, 11:28 AM EDT
Recruiting Phase 4 Interventional

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

NCT07569926
View directory record Official record
Conditions
Prostate Cancer
Interventions
fluciclovine (18F)
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older · Male only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 29, 2026, 11:28 AM EDT
Not listed Phase 3 Interventional

18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy

NCT05479136
View directory record Official record
Conditions
Grade III or Grade IV Glioma
Interventions
PET imaging with 18F fluciclovine
Drug
Lead sponsor
Nicole Hill
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 29, 2026, 11:28 AM EDT
Terminated Phase 2 Interventional Results available

FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer

NCT00917865
View directory record Official record
Conditions
Prostate Cancers
Interventions
anti [18F]FACBC
Drug
Lead sponsor
David M. Schuster, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Sep 29, 2026, 11:28 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NCT05053152
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy
Procedure · Other · Drug + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
242
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 29, 2026, 11:28 AM EDT
Completed Phase 3 Interventional Results available

18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

NCT02680041
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-fluciclovine PET CT
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older · Male only
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Sep 29, 2026, 11:28 AM EDT
Completed Phase 1 Interventional Results available

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

NCT04750473
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Computed Tomography, Fluciclovine F18, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 29, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Results available

Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)

NCT04410367
View directory record Official record
Conditions
Brain Metastases
Interventions
18F fluciclovine
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 29, 2026, 11:28 AM EDT
Terminated Phase 2 Interventional Results available

GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

NCT01176513
View directory record Official record
Conditions
Prostate Cancer
Interventions
GE-148 (18F)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 29, 2026, 11:28 AM EDT
Recruiting Phase 2 Interventional

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

NCT05554302
View directory record Official record
Conditions
Brain Metastases, Brain Cancer
Interventions
18F-Fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 29, 2026, 11:28 AM EDT
Completed Not applicable Interventional

F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery

NCT03926507
View directory record Official record
Conditions
Glioblastoma
Interventions
Computed Tomography, Fluciclovine F18, Positron Emission Tomography
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 29, 2026, 11:28 AM EDT
Terminated Phase 4 Interventional Results available

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

NCT04134208
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Fluciclovine F18, Positron Emission Tomography
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 29, 2026, 11:28 AM EDT
Completed Not applicable Interventional Results available

Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma

NCT03496844
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
F-18 fluciclovine-PET/CT scan
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Sep 29, 2026, 11:28 AM EDT
Completed Phase 3 Interventional Results available

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

NCT04410133
View directory record Official record
Conditions
Brain Metastases
Interventions
18F fluciclovine
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 29, 2026, 11:28 AM EDT
Recruiting Early Phase 1 Interventional

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

NCT06613841
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme of Brain
Interventions
Fluciclovine F18
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 29, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Results available

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

NCT04158245
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
18F-fluciclovine PET Scan
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 18 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 29, 2026, 11:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

NCT03276676
View directory record Official record
Conditions
Brain Tumor
Interventions
[18F]FLT, [18F]Fluciclovine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 29, 2026, 11:28 AM EDT
Recruiting Phase 2 Interventional

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT06103838
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
18F-fluciclovine injection, 18F-FDG PET/CT
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 29, 2026, 11:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

FACBC Outcomes for Post Prostatectomy

NCT01666808
View directory record Official record
Conditions
Prostate Cancer
Interventions
FACBC, Radiation therapy
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years · Male only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Sep 29, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Results available

Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease

NCT03081884
View directory record Official record
Conditions
Cancer
Interventions
FACBC PET-CT Imaging
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 29, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Results available

FACBC Prostate Therapy Response

NCT02830880
View directory record Official record
Conditions
Prostate Cancer
Interventions
FACBC PET-CT, MRI, CT, or Bone Scan
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 29, 2026, 11:28 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Defining Recurrent Disease With Axumin™

NCT03996993
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Casodex, Axumin, Salvage Radiation, Axumin
Drug · Radiation
Lead sponsor
Cancer Center of Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 29, 2026, 11:28 AM EDT
Recruiting Phase 1 Interventional

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

NCT04689048
View directory record Official record
Conditions
Brain Metastases, Adult, Brain Metastases, Brain Cancer
Interventions
18F fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 29, 2026, 11:28 AM EDT